DO-BO

How to decode Market Access in Canada: Are there essential tips for success, Tara Cowling and Jody Filkowski?

In the newest episode of MAP – the Market Access podcast, experts Tara Cowling and Jody Filkowski unpacks the complexities and nuances of Canada’s market access for pharmaceuticals and medical devices. From regulatory hurdles to intricate reimbursement pathways, they shed light on what it takes to successfully navigate this diverse and challenging landscape.

Whether you’re dealing with drugs or medical devices, understanding the distinct processes in Canada, including the differences between provinces and the role of private versus public payers, is crucial. This episode offers a deep dive into the practical strategies and real-world challenges faced by industry professionals working within the Canadian healthcare system. They also share insights about the emerging role of digital health in Canada, and the potential changes with the introduction of the Canadian Drug Agency.

Related

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]

From Olympic ice to AI-powered leadership: What can Market Access teams learn from elite sports? In the 111+1 anniversary episode of MAP – the Market Access Podcast, Dr. Stefan Walzer interviews Livia Altmann, a former Swiss Olympic ice hockey player who has transitioned into a leadership and “Human Intelligence 2.0” expert. Together, they explore how […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world evidence and market access. Together they unpack how the UK NICE threshold increase (from £20–30k to £25–35k per QALY) and US reforms (IRA, MFN) are quietly […]